CN110305161A - 2- amino-metadiazine compound and its application - Google Patents
2- amino-metadiazine compound and its application Download PDFInfo
- Publication number
- CN110305161A CN110305161A CN201910208004.1A CN201910208004A CN110305161A CN 110305161 A CN110305161 A CN 110305161A CN 201910208004 A CN201910208004 A CN 201910208004A CN 110305161 A CN110305161 A CN 110305161A
- Authority
- CN
- China
- Prior art keywords
- amino
- phenyl
- chloro
- base
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2- amino-metadiazine compound Chemical class 0.000 title claims abstract description 301
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 239000003112 inhibitor Substances 0.000 claims abstract description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 327
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 215
- SGTQXKBRULHMLI-UHFFFAOYSA-N (methyl-$l^{2}-phosphanyl)methane Chemical compound C[P]C SGTQXKBRULHMLI-UHFFFAOYSA-N 0.000 claims description 206
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 55
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 54
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 27
- 229910021529 ammonia Inorganic materials 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 25
- 229940002612 prodrug Drugs 0.000 claims description 25
- 239000000651 prodrug Substances 0.000 claims description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 21
- 229910052801 chlorine Inorganic materials 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000000470 constituent Substances 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 7
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 6
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- QHVYJSBQXIIROJ-KNVOCYPGSA-N (2s,6r)-1,2,6-trimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1C QHVYJSBQXIIROJ-KNVOCYPGSA-N 0.000 claims description 3
- YQURLNGUWNDBIR-KNVOCYPGSA-N (3as,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole Chemical class C1NC[C@@H]2CN(C)C[C@@H]21 YQURLNGUWNDBIR-KNVOCYPGSA-N 0.000 claims description 3
- UNGUQQBXDOAOQO-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)piperazine Chemical compound C=1C=CN=CC=1CN1CCNCC1 UNGUQQBXDOAOQO-UHFFFAOYSA-N 0.000 claims description 3
- WGIAYBNWTYECJD-UHFFFAOYSA-N 1-ethoxypiperazine Chemical compound CCON1CCNCC1 WGIAYBNWTYECJD-UHFFFAOYSA-N 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- WGNPNAOPVBYTKD-UHFFFAOYSA-N 4-pyrazol-1-ylpiperidine Chemical class C1CNCCC1N1N=CC=C1 WGNPNAOPVBYTKD-UHFFFAOYSA-N 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000001273 butane Substances 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- MEZKKZTWNNWYBQ-UHFFFAOYSA-N n'-methyl-n'-propylethane-1,2-diamine Chemical compound CCCN(C)CCN MEZKKZTWNNWYBQ-UHFFFAOYSA-N 0.000 claims description 3
- JPJBURDLVZPQQP-UHFFFAOYSA-N n,n-diethyl-2-pyrazol-1-ylethanamine Chemical class CCN(CC)CCN1C=CC=N1 JPJBURDLVZPQQP-UHFFFAOYSA-N 0.000 claims description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 150000002921 oxetanes Chemical class 0.000 claims description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 claims description 3
- 208000020615 rectal carcinoma Diseases 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 4
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical class NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- XWINCPYLXQTPQV-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1.C1CNCCN1 XWINCPYLXQTPQV-UHFFFAOYSA-N 0.000 claims 2
- SFFUEHODRAXXIA-UHFFFAOYSA-N 2,2,2-trifluoroacetonitrile Chemical compound FC(F)(F)C#N SFFUEHODRAXXIA-UHFFFAOYSA-N 0.000 claims 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 17
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 abstract description 8
- 102000001253 Protein Kinase Human genes 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 108060006633 protein kinase Proteins 0.000 abstract description 4
- 229940121657 clinical drug Drugs 0.000 abstract description 2
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 abstract description 2
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229950000778 olmutinib Drugs 0.000 abstract description 2
- 239000002585 base Substances 0.000 description 141
- 238000010189 synthetic method Methods 0.000 description 64
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 235000002639 sodium chloride Nutrition 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 15
- 229940060038 chlorine Drugs 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 206010059866 Drug resistance Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 229940121647 egfr inhibitor Drugs 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000011257 shell material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229940121649 protein inhibitor Drugs 0.000 description 4
- 239000012268 protein inhibitor Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- SHEQRWTUXYWGQS-UHFFFAOYSA-N 2-dimethylphosphanylaniline Chemical compound CP(C)C1=CC=CC=C1N SHEQRWTUXYWGQS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000013038 irreversible inhibitor Substances 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960003278 osimertinib Drugs 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CEJAHXLRNZJPQH-UHFFFAOYSA-N 2,5-dichloropyrimidine Chemical compound ClC1=CN=C(Cl)N=C1 CEJAHXLRNZJPQH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RJWUMFHQJJBBOD-UHFFFAOYSA-N 2-methylheptadecane Chemical compound CCCCCCCCCCCCCCCC(C)C RJWUMFHQJJBBOD-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 108700020746 histrelin Proteins 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940087004 mustargen Drugs 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960002812 sunitinib malate Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 239000001533 (4R,6S)-2,4,6-trimethyl-1,3,5-dithiazinane Substances 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
- DNTHMWUMRGOJRY-UHFFFAOYSA-N 1-fluoro-4-nitro-2-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(C(F)(F)F)=C1 DNTHMWUMRGOJRY-UHFFFAOYSA-N 0.000 description 1
- FFXOQCRWOVUFJV-UHFFFAOYSA-N 1-methyl-4-piperidin-4-ylpiperazine;hydrochloride Chemical compound Cl.C1CN(C)CCN1C1CCNCC1 FFXOQCRWOVUFJV-UHFFFAOYSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- FVVPWVFWOOMXEZ-ZIADKAODSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 FVVPWVFWOOMXEZ-ZIADKAODSA-N 0.000 description 1
- RVDMKYVYEXBJNC-UHFFFAOYSA-N 4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3-(trifluoromethyl)aniline Chemical compound C1CN(C)CCN1C1CCN(C=2C(=CC(N)=CC=2)C(F)(F)F)CC1 RVDMKYVYEXBJNC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- OGWKCGZFUXNPDA-CFWMRBGOSA-N 5j49q6b70f Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 OGWKCGZFUXNPDA-CFWMRBGOSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940124204 C-kit inhibitor Drugs 0.000 description 1
- NTZRDKVFLPLTPU-UHFFFAOYSA-N CC[Na] Chemical compound CC[Na] NTZRDKVFLPLTPU-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108091069885 IAP family Proteins 0.000 description 1
- 102000040104 IAP family Human genes 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 190014017285 Satraplatin Chemical compound 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FBMVFHKKLDGLJA-UHFFFAOYSA-N Thialdine Chemical compound CC1NC(C)SC(C)S1 FBMVFHKKLDGLJA-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229940060516 alferon n Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical class [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229950001357 celmoleukin Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940087158 gilotrif Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 229950008642 miproxifene Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- RRHNGIRRWDWWQQ-UHFFFAOYSA-N n-iodoaniline Chemical group INC1=CC=CC=C1 RRHNGIRRWDWWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- RBJROVWIRLFZFC-PNLFXGMVSA-N prednisolone steaglate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)COC(=O)CCCCCCCCCCCCCCCCC)(O)[C@@]1(C)C[C@@H]2O RBJROVWIRLFZFC-PNLFXGMVSA-N 0.000 description 1
- 229950010987 prednisolone steaglate Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229950007649 ranpirnase Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229940063635 salagen Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229940111100 tice bcg Drugs 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950010938 valspodar Drugs 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of 2- amino-metadiazine compound and its applications, and the structure of 2- amino-metadiazine compound is as shown in I.Such compound can effectively inhibit EGFR protein kinase drug resistant mutants (such as EGFRT790MAnd EGFRT790M/C797S) activity, and existing third generation selectivity EGFR can be overcomeT790MThe clinical drug-resistant of the tumour patients such as micromolecular inhibitor Osimertinib (AZD9291), Olmutinib (HM6171), Rociletinib (CO-1686) etc. the non-small cell lung cancer of inductions.
Description
Technical field
The present invention relates to chemical medicines, more particularly to a kind of 2- amino-metadiazine compound and its application.
Background technique
Tumor cells targeted therapy be based on to the closely related key molecule of tumour growth by chemistry or biology learn to do
A kind for the treatment of method of section selective killing tumour cell.The characteristics of targeted therapy are as follows: specificity is high, and selectivity is strong, and poison is secondary to be made
With relatively gently;When use in conjunction, it can reinforce the curative effect of classic chemotherapy, radiotherapy, reduce postoperative recurrence.With Gleevec
(STI571) (Novartis, 2001), Gefitinib (ZD1839) (AstraZeneca, 2003), Erlotinib (OSI774)
(Genentech and OSIP, 2004), Sorafenib tosilate (Bay 43-9006) (Bayer and Onyx,
2005), sunitinib malate (SU11248) (Pfizer, 2006) and Dasatinib (BMS-354825) (Bristol-
Myers Squibb, 2006) it is that the targeted drug represented has started a new era as chemotherapy of tumors.Neoplasm targeted therapy exists
It is rapidly developed in a few years.Going out for neoplasm targeted therapy constitutes impact, example to convenient administration idea and mode
Such as, because the small targeted drug of toxic side effect is often unable to reach dose-limiting toxicity and maximum tolerance agent in Phase I clinical trial
Amount;With when target therapeutic agent without with maximum tolerated dose can reach satisfactory effect.Neoplasm targeted therapy is oncotherapy
Hot spot and development trend.
EGF-R ELISA (EGFR), a kind of receptor tyrosine protein kinase have regulated and controled the proliferation of cell, survival,
Adhesion, migration and differentiation.EGFR overactivity or continuous activation in kinds of tumor cells, such as lung cancer, breast cancer, prostate
Cancer etc..There are EGFR overexpressions for about 62% Patients with Non-small-cell Lung, can significantly improve part to the inhibition of EGFR and suffer from
The life cycle of person.Also, EGFR micromolecular inhibitor the drug Gefitinib and Erlotinib of listing in 2003~2004 years,
It is used for the treatment of advanced Non-small cell lung, having further clarified EGFR is the Effective target site for treating non-small cell lung cancer.
First generation EGFR micromolecular inhibitor obtains significant clinical efficacy in the patient for carrying EGFR sensitizing mutation,
Extend their life cycle.But benefit patient after using drug 10~12 months, most of patient can generate drug resistance.Its
In, the drug resistance patient (carrying EGFR sensitizing mutation) more than 50% is that bis- mutation of T790M have occurred due to EGFR to generate drug resistance.
Compared to the EGFR of L858R sensitizing mutation, the EGFR of L858R/T790M bis- times mutation is stronger to the affinity of ATP, and first generation medicine
Object is ATP competitive inhibitor, therefore leads to Drug-resistant.Although second generation EGFR irreversible inhibitor is in preclinical study
It obtains preferable as a result, but to Wild type EGFR (EGFRWT) lack selectivity, there is larger toxicity.FDA approval in 2013
Although EGFR irreversible inhibitor Gilotrif is to the advanced stage for carrying activity EGFR mutation (L858R, del E746-A750)
Patient NSCLC is effective, but at clinical maximum tolerated dose (MTD), can not still solve clinical caused by EGFRT790M mutation
Drug resistance.The third generation overcomes EGFRT790MDrug resistant irreversible inhibitor Osimertinib (AZD9291) is obtained in November, 2015
It obtains U.S. FDA and accelerates approval listing (Cancer discovery 2014,4 (9), 1046-1061), can clinically have
Effect treatment EGF-R ELISA (EGFR) T790M is mutated or to the drug resistant Advanced Non-Small Cell lung of other EGFR inhibitors
Cancer patient.Although Osimertinib clinically treat EGFRT790M mutation non-small cell lung cancer achieve it is biggish at
Function, but is there is the phenomenon that drug resistance (Nature Medicine after treatment in 9~14 months again in part benefited patient
2015,21(6),560-2).It has been investigated that up to 40% drug resistance patient is resulted in due to (EGFR) C797S point mutation
Osimertinib drug resistance.Further Mechanism Study shows that the point mutation of (EGFR) C797S turns 797 cysteines
Become serine, causes Osimertinib that can not form covalent bond with target protein, finally cause drug resistance.It is clinical at present still to lack
It is weary to be directed to the effective EGFR inhibitor of new mutation (C797S) independent medication.Therefore, there is an urgent need to new types, highly selective
EGFR inhibitor is come the problems such as solving drug resistance caused by (EGFR) C797S point mutation.
Summary of the invention
Based on this, the present invention provides a kind of 2- amino-metadiazine compound, such compound can effectively inhibit EGFR
Protein kinase drug resistant mutants (such as EGFRT790MAnd EGFRT790M/C797S) activity.
Specific technical solution is as follows:
2- amino-metadiazine compound or its pharmaceutically acceptable salt or its solid with structure shown in Formulas I are different
Structure body or its prodrugs:
In formula:
D, E, F, W, X, Y, Z are separately selected from: CH or N;
R1And R2It is separately selected from: H, halogen, cyano, trifluoromethyl, nitro, substituted or unsubstituted C1-C6Alkane
Base, substituted or unsubstituted C3-C6Naphthenic base, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C3-C6Cycloalkanes
Oxygroup;
R3It is selected from: hydrogen, halogen, cyano, trifluoromethyl, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-
C6Naphthenic base, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C3-C6Cycloalkyloxy;
R4It is selected from: substituted or unsubstituted pyrazolyl ,-(CH2)mNR6R7、-(CH2)mOCR5R6R7、-(CH2)mCR5R6R7;
Wherein, m is selected from: 0,1,2,3 or 4;
R5It is selected from: hydrogen or C1-C3Alkyl;
R6And R7It is separately selected from: hydrogen, substituted or unsubstituted C1-C6Alkyl or R6、R7With the N or C being connected
It is formed together substituted or unsubstituted containing heteroatomic monocycle or condensed ring.
In wherein some embodiments, R4It is selected from: R8Substituted pyrazolyl ,-(CH2)mNR6R7、-(CH2)mOCR5R6R7、 -
(CH2)mCR5R6R7;Wherein, m is selected from: 0,1,2,3 or 4;
R5It is selected from: hydrogen or C1-C3Alkyl;
R6And R7It is separately selected from: hydrogen, R8Substituted C1-C6Alkyl or R6、R7It is formed together with the N or C being connected
R8What is replaced contains n heteroatomic 3-8 unit monocycles or R6、R7R is formed together with the N or C being connected8What is replaced contains n miscellaneous originals
8-12 member condensed ring, loop coil or bridged ring, the n of son are selected from: 1,2 or 3, hetero atom is selected from: O, N, S;
R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, halogen, hydroxyl, amino, C1-C3Alkyl ,-C (=O) NHR9Replace
C1-C3The C that alkyl, hydroxyl replace1-C3Alkyl, C3-C6The C that naphthenic base replaces1-C3Alkyl, C3-C8The C that heterocycle replaces1-C3Alkane
Base, C1-C3Alkoxy ,-NHR9、-N(R9)2,-C (=O) R9;R9For C1-C3Alkyl.
In wherein some embodiments, R4It is selected from :-(CH2)mNR6R7;M is selected from: 0 or 1;
R6And R7It is separately selected from: hydrogen, R8Substituted C1-C6Alkyl or R6、R7R is formed together with the N being connected8
What is replaced contains n heteroatomic 3-8 unit monocycles or R6、R7R is formed together with the N being connected8What is replaced contains n heteroatomic 8-
12 yuan of condensed ring, loop coil or bridged ring, wherein n is selected from: 1,2 or 3, hetero atom is selected from: O, N, S;
R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, halogen, hydroxyl, amino, C1-C3Alkyl, C1-C3Alkoxy ,-
NHR9、 -N(R9)2,-C (=O) R9;R9For C1-C3Alkyl.
In wherein some embodiments, R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, C1-C3Alkyl ,-NHR9、-N
(R9)2; R9For C1-C3Alkyl.
In wherein some embodiments, R4It is selected from:
In wherein some embodiments, F is selected from: CH or N;D, E, W, X, Y, Z are CH.
In wherein some embodiments, R1And R2It is separately selected from: H, halogen, cyano, trifluoromethyl, nitro, C1-
C6Alkyl, C3-C6Naphthenic base, C1-C6Alkoxy, C3-C6The C that cycloalkyloxy, halogen replace1-C6The C that alkyl, halogen replace1-C6
Alkoxy.
In wherein some embodiments, R1It is selected from: halogen, methyl, cyano, trifluoromethyl, difluoromethyl, methoxyl group, ring
Propyl, trifluoromethoxy.
In wherein some embodiments, R2It is selected from: halogen, C1-C6Alkyl, fluorine-substituted C1-C6Alkyl, C3-C6Naphthenic base,
Fluorine-substituted C3-C6Naphthenic base, C1-C6Alkoxy, fluorine-substituted C1-C6Alkoxy.
In wherein some embodiments, R2It is selected from: fluorine, chlorine, bromine, methyl, ethyl, methoxyl group, trifluoromethyl, difluoro first
Base, trifluoromethoxy, cyclopropyl, isopropyl, n-propyl.
In wherein some embodiments, R3It is selected from: hydrogen, halogen, cyano, trifluoromethyl, nitro, C1-C6Alkyl, C3-C6Ring
Alkyl, C1-C6Alkoxy, C3-C6The C that cycloalkyloxy, halogen replace1-C6The C that alkyl, halogen replace1-C6Alkoxy.
In wherein some embodiments, R3Be selected from: hydrogen, fluorine, chlorine, methyl, ethyl, cyano, trifluoromethyl, difluoromethyl,
Methoxyl group, cyclopropyl, trifluoromethoxy.
In wherein some embodiments, the 2- amino-metadiazine compound is selected from:
(((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- trifluoromethyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -3- aminomethyl phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3aR, 6aS) -5- methyl hexahydropyrrolo [3,4-c] pyrroles -2 (1H)-yl)
Phenyl) amino) pyrimidine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methyl-1,4- phenodiazine heptane -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(((the chloro- 2- of 5- ((3- methoxyl group -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (9- methyl -3,9- phenodiazine spiral shell [5.5] hendecane -3- base) phenyl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(((the chloro- 2- of 5- ((3- methyl -4- (7- methyl -2,7- phenodiazine spiral shell [3.5] nonane -2- base) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(S)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(R)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- ((2- (dimethylamino) ethyl) (methyl) amino) -6- picoline -2- base) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3R, 5S) -3,4,5- tri methyl piperazine -1- base) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((1- (2- (diethylamino) ethyl) -1H- pyrazoles -4- base) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (oxetanes -3- base) piperazine -1- base) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- (piperazine -1- ylmethyl) pyridine -2- base) amino) pyrimidine-4-yl) amino) phenyl) two
Methyl oxidation phosphorus;
(2- ((the chloro- 2- of 5- ((3- methoxyl group -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- ethyl piperazidine -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((2- ((the bromo- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) -5- chlorine pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((2- ((the bromo- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- chlorine pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((6- methyl -5- (4- methylpiperazine-1-yl) pyridine 2- yl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((5- chlorine 2- ((3- methyl -4- (piperidin-4-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl
Phosphorous oxide;
(2- ((the chloro- 2- of 5- ((4- (4- (dimethylamino) piperidin-1-yl) -3- aminomethyl phenyl) amino) pyrimidine 4- yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- methylpiperazine-1-yl) -3- trifluoromethyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the fluoro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- morpholino phenyl of 3-) amino) pyrimidine-4-yl) amino) phenyl) dimethyl
Phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2- base)
Phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
1- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) benzene
Base) piperazine -1- base) ethyl -1- ketone;
2- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) benzene
Base) piperazine -1- base)-N- methylacetamide;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (2- ethoxy) piperazine -1- base) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- hydroxy piperidine -1- base) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) heterocyclic butane -1- base) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (methyl (2- (methylamino) ethyl) amino) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (cyclopropyl alkyl methyl) piperazine -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2-
Base) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- morpholinyl piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methyl-1,4- diaza heptane -1- base) piperidin-1-yl) phenyl) ammonia
Base) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (piperidin-1-yl) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (pyrrolidin-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(((2- ((4- (4- (azetidine -1- ylmethyl) piperidin-1-yl) -3- chlorphenyl) amino) -5- chlorine is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((2- ((4- ([bis- piperidines of 1,4'-] -1'- base) -3- chlorphenyl) amino) -5- chlorine pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- chlorine 4- (3- (pyrrolidin-1-yl) propoxyl group) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methylpyrrolidin- 3- yl) oxygroup) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methyl piperidine -4- base) oxygroup) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (1- (piperidin-4-yl) -1H- pyrazoles -4- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- (trifluoromethyl)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the bromo- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -4- ((2- (solutions of dimethyl phosphoryl
Base) phenyl) amino) pyrimidine -5- formonitrile HCN;
(((the chloro- 2- of 5- ((3- cyclopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(((the chloro- 2- of 5- ((3- difluoromethyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- (trifluoromethoxy) phenyl) ammonia
Base) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- ethyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(((the chloro- 2- of 5- ((3- isopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- propyl phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridin-3-yl) dimethyl phosphorus;
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridin-4-yl) dimethyl phosphorus;
(4- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -3-
Base) amino) pyridin-4-yl) dimethyl phosphorus;
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridine -2- base) dimethyl phosphorus.
The present invention also provides 2- amino-metadiazine compound or its pharmaceutically acceptable salt or its alloisomerisms
The application of body or its prodrugs.
Specific technical solution is as follows:
Above-mentioned 2- amino-metadiazine compound or its pharmaceutically acceptable salt or its stereoisomer or its
Prodrugs are preparing the application in mutant egf R inhibitor.
Above-mentioned 2- amino-metadiazine compound or its pharmaceutically acceptable salt or its stereoisomer or its
Application of the prodrugs in the drug for preparing anti-curing oncoma.
In wherein some embodiments, the tumour is the malignant tumour of EGFR genetic mutation.
In wherein some embodiments, the tumour is EGFRL858R/T790M/C797SThe malignant tumour of mutation.
In wherein some embodiments, the tumour are as follows: non-small cell lung cancer, Small Cell Lung Cancer, adenocarcinoma of lung, lung squamous cancer,
Cancer of pancreas, breast cancer, prostate cancer, liver cancer, cutaneum carcinoma, cell carcinoma, gastrointestinal stromal tumor, leukaemia, histiocytic leaching
Bar cancer, nasopharyngeal carcinoma, head and neck neoplasm, colon and rectum carcinoma or glioma.
The present invention also provides a kind of pharmaceutical compositions of anti-curing oncoma.
Specific technical solution is as follows:
A kind of pharmaceutical composition of anti-curing oncoma, including active constituent and pharmaceutically acceptable carrier, the activity
Ingredient include above-mentioned 2- amino-metadiazine compound or its pharmaceutically acceptable salt or its stereoisomer or
Its prodrugs.
2- amino-metadiazine compound or its pharmaceutically acceptable salt of the invention or its stereoisomer or
Its prodrugs can generate inhibiting effect to EGFR family protein enzyme, so as to inhibit the growth of kinds of tumor cells.It is right
Than wild type cancer cell, the compound of the present invention is to saltant type cancer cell selectivity with higher.The compound of the present invention is outstanding
It can effectively inhibit EGFR protein kinase drug resistant mutants (such as EGFRT790MAnd EGFRT790M/C797S) activity, can select
Property acts on EGFRL858R/T790M、EGFRDelE745_A750And EGFRL858R/T790MC797SLung carcinoma cell can overcome existing third
Generation selectivity EGFRT790MMicromolecular inhibitor Osimertinib (AZD9291), Olmutinib (HM6171), Rociletinib
(CO-1686) clinical drug-resistant of the tumour patients such as non-small cell lung cancer of inductions such as.
The compound of the present invention can be used for preparing anti-tumor drug, and existing drug Gefitinib, Lip river in distress can be overcome to replace
The drug resistance of the inductions such as Buddhist nun, especially Osimertinib (AZD9291), which is that one kind is novel, can overcome existing EGFR tyrosine
Kinase inhibitor it is drug resistant and have selectivity and good medicine for property kinases inhibitor, can be used for treating the mankind and its
The excess proliferative diseases such as the tumour of its mammal.
Detailed description of the invention
Fig. 1 is part of compounds of the invention to containing EGFRL858R/T790M/C797SThe BaF3EGFR of mutationL858R/T790M/C797S
The inhibiting effect test result of kinases in vehicles cells.
Fig. 2 is part of compounds of the invention to containing EGFR19D/T790M/C797SThe BaF3EGFR of mutation19D/T790M/C797STool
The inhibiting effect test result of kinases in cell.
Specific embodiment
In compound of the present invention, as any variable (such as R6、R7Deng) occur more than in any component it is primary, then
Its definition occurred every time is independently of other definition occurred every time.Equally, the combination for allowing substituent group and variable, as long as this
Combination stablizes compound.The line for being divided into loop system from substituent group indicates that signified key may be connected to any annular atom that can replace
On.If loop system be it is polycyclic, it means that this key is connected only on any carbon atom appropriate of adjacent loops.It is appreciated that this
Field those of ordinary skill may be selected the substituent group of the compounds of this invention and replace form and provide chemically stable and can lead to
The compound that the method for crossing art technology and following proposition is readily synthesized from readily available raw material.If substituent group is certainly
Body is exceeded a group and replaces, it should be understood that these groups can be in identical carbon atoms or on different carbon atoms, as long as making structure
Stablize.Phrase " being replaced by substituent group selected from the group below " is considered with phrase " being replaced by least one substituent group " quite, and
Preferred embodiment will have 1-4 substituent group in the case of this.
Terms used herein " alkyl " mean include have particular carbon atom number branch and straight chain saturated fat
Alkyl.For example, " C1-C6" C in alkyl "1-C6" definition include with linear chain or branched chain arrangement have 1,2,3,4,5 or 6 carbon
The group of atom.For example, " C1-C6Alkyl " specifically includes methyl, ethyl, n-propyl, isopropyl, normal-butyl, tert-butyl, isobutyl
Base, amyl, hexyl.Term " naphthenic base " refers to the monocycle saturated fat alkyl with particular carbon atom number.Such as " naphthenic base "
Including cyclopropyl, cyclobutyl, cyclopenta or cyclohexyl etc..Term " alkoxy " refers to the group with-O- alkyl structure, as-
OCH3、 -OCH2CH3、-OCH2CH2CH3、-O-CH2CH(CH3)2、-OCH2CH2CH2CH3、-O-CH(CH3)2Deng.
As will be appreciated by a person skilled in the art, " halogen " used herein (" halo ") or " halogen " mean chlorine, fluorine, bromine
And iodine.
The present invention provides a kind of compound of formula I, pharmaceutically acceptable salt or its stereoisomer or its prodrugs,
Wherein, R1、R2、R3、R4It is as defined above with D, E, F, W, X, Y, Z.
The present invention includes the free form of compound of formula I, also includes its pharmaceutically acceptable salt and stereoisomer.This
Some specific exemplary compounds are the salt of the protonation of aminated compounds in text.Term " free form " refers to salt-independent shape
Aminated compounds.The pharmaceutically-acceptable salts being included not only include the exemplary salt of specific compound described herein,
Typical pharmaceutically acceptable salt including all compound of formula I free forms.Techniques known in the art can be used to separate institute
State the free form of compound specific salts.For example, can be by with alkali dilute aqueous solution appropriate such as NaOH dilute aqueous solution, potassium carbonate
Dilute aqueous solution, weak aqua ammonia and sodium bicarbonate dilute aqueous solution, which handle the salt, regenerates free form.Free form is certain physical
Matter for example in polar solvent respectively more or less distinguish with its in solubility by salt form, but is this hydrochlorate of purpose of invention
And respectively free form is suitable with its in terms of other pharmacy for alkali salt.
It can be synthesized by conventional chemical processes from the compounds of this invention containing alkaline part or acidic moiety of the invention
Pharmaceutically acceptable salt.In general, by ion-exchange chromatography or passing through free alkali and stoichiometric amount or excessive required salt
The reaction in the combination of appropriate solvent or multi-solvents of the inorganic or organic acid of form prepares the salt of alkali compounds.Similar,
The salt of acid compound is formed by reacting with appropriate inorganic or organic base.
Therefore, the pharmaceutically acceptable salt of the compounds of this invention includes by alkaline the compounds of this invention and inorganic or have
Machine acid reacts the conventional non-toxic salts for the compounds of this invention to be formed.For example, conventional nontoxic salts include deriving from inorganic acid such as salt
The salt of acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid etc. also includes from organic acid such as acetic acid, propionic acid, succinic acid, second
Alkyd, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, flutter acid, maleic acid, hydroxymaleic acid, phenylacetic acid,
Glutamic acid, benzoic acid, salicylic acid, p-aminobenzene sulfonic acid, one benzoic acid of 2- acetoxyl group, fumaric acid, toluenesulfonic acid, methanesulfonic acid,
The salt of the preparations such as ethane disulfonic acid, oxalic acid, isethionic acid, trifluoroacetic acid.
If the compounds of this invention be it is acid, " pharmaceutically acceptable salt " appropriate refers to by pharmaceutically acceptable
Nontoxic alkali include inorganic base and organic base preparation salt derive from inorganic base salt include aluminium salt, ammonium salt, calcium salt, mantoquita, iron
Salt, ferrous salt, lithium salts, magnesium salts, manganese salt, manganous salt, sylvite, sodium salt, zinc salt etc..Particularly preferred ammonium salt, calcium salt, magnesium salts, sylvite
And sodium salt.Salt derived from pharmaceutically acceptable organic nontoxic alkali, the alkali includes the salt of primary amine, secondary amine and tertiary amine, substituted
Amine include naturally occurring substitution amine, cyclic amine and deacidite for example arginine, glycine betaine, caffeine, choline,
N, N'- dibenzyl-ethylenediamin, diethylamine, 2- DEAE diethylaminoethanol, 2-dimethylaminoethanol, ethylaminoethanol, ethanol amine, second
Diamines, N-ethylmorpholine, N-ethylpiperidine, gucosamine, Glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine,
Methyl glucose osamine, morpholine, piperazine, piperidines, croak smack one's lips, polyamines resin, procaine, purine, theobromine, triethylamine, trimethylamine,
Tripropyl amine (TPA), tromethamine etc..
Berg etc., " Pharmaceutical Salts " J.Pharm.Sci. ' 1977:66:1-19 are described in more detail
The preparation of the literary pharmaceutically acceptable salt and other typical pharmaceutically acceptable salts.
Since the acidic moiety such as carboxyl of deprotonation in compound in physiological conditions can be anion, and it is this
The charge having then can be by the internal protonated or alkylated alkaline part such as quaternary nitrogen atom with cation
Balance is offset, it is noted that the compounds of this invention is potential inner salt or amphoteric ion.
Except known in the literature or in addition to the standard method of illustration, can be used in following specific embodiment in experimental arrangement
The reaction that listed scheme is shown prepares the compounds of this invention.Therefore, following illustrative approach is the purpose to illustrate rather than office
It is limited to listed compound or any specific substituent group.The substituent group number shown in scheme not necessarily meets in claim
Number used, and for clarity, showing monosubstituted base to be connected under the hereinbefore definition of Formulas I allows to have multi-substituent
On compound.
Compound and its pharmaceutically acceptable salt provided by the invention with Formulas I structure can be used for treating people or other
The transition such as mammal tumor proliferative diseases or symptom.In particular for treating or controlling non-small cell lung cancer, cellule lung
It is cancer, adenocarcinoma of lung, lung squamous cancer, cancer of pancreas, breast cancer, prostate cancer, liver cancer, cutaneum carcinoma, cell carcinoma, gastrointestinal stromal tumor, white
The transition proliferative diseases such as blood disease, histiocytic lymph cancer, nasopharyngeal carcinoma, head and neck neoplasm, colon and rectum carcinoma, glioma.
Drug metabolite and prodrug: the metabolite of compound and its pharmaceutically acceptable salt according to the present invention,
And the prodrug of the structure of compound according to the present invention and its pharmaceutically acceptable salt can be changed into vivo, also include
In claims hereof.
Pharmaceutical composition: the present invention also provides a kind of pharmaceutical compositions, it includes the activity within the scope of safe and effective amount
Ingredient and pharmaceutically acceptable carrier." active constituent " of the present invention refers to compound of formula I of the present invention.
" active constituent " of the present invention and pharmaceutical composition can be used as EGFR protease inhibitors.In another preference
In, it is used to prepare prevention and/or treats the drug of tumour.
" safe and effective amount " refers to: the amount of active constituent is enough to be obviously improved the state of an illness, and is unlikely to generate serious pair
Effect.In general, pharmaceutical composition contains 1-2000mg active constituent/agent, more preferably, contain 10-200mg active constituent/agent.Compared with
Goodly, it is described it is " one " be a tablet.
" pharmaceutically acceptable carrier " refers to: one or more biocompatible solids or liquid filler or gelatinous mass,
They are suitable for people's use and it is necessary to have enough purity and sufficiently low toxicity.
In " compatibility " referred to herein as composition each component energy and active constituent of the invention and they between mutually
Blending, and significantly reduce the drug effect of active constituent.
Pharmaceutically acceptable carrier part example has cellulose and its derivates (such as sodium carboxymethylcellulose, ethyl
Sodium cellulosate, cellulose ethanoate etc.), gelatin, talcum, solid lubricant (such as stearic acid, magnesium stearate), calcium sulfate, plant
Oily (such as soya-bean oil, sesame oil, peanut oil, olive oil), polyalcohol (such as propylene glycol, glycerol, mannitol, sorbierite), emulsification
Agent (such as tween), wetting agent (such as lauryl sodium sulfate), colorant, flavoring agent, stabilizer, antioxidant, preservative,
Apirogen water etc..
In another preferred example, formula Compound I can be acted on macromolecular compound or macromolecule by nonbonding
Form compound.In another preferred example, formula Compound I can also pass through chemical bond and macromolecular chemical combination as small molecule
Object or macromolecule are connected.The macromolecular compound can be large biological molecule such as high glycan, albumen, nucleic acid, polypeptide etc..
The method of application of active constituent or pharmaceutical composition of the invention is not particularly limited, representative method of application packet
Include (but being not limited to): in oral, tumor, rectum, parenteral (intravenous, intramuscular or subcutaneous) etc..
Solid dosage forms for oral administration includes capsule, tablet, pill, powder and granule.
In these solid dosage forms, active constituent is mixed at least one conventional inert excipients (or carrier), such as lemon
Sour sodium or Dicalcium Phosphate, or mixed with following compositions:
(a) filler or expanding material, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid;
(b) adhesive, for example, hydroxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and Arab
Glue;
(c) moisturizer, for example, glycerol;
(d) disintegrating agent, for example, agar, calcium carbonate, potato starch or tapioca, alginic acid, certain composition silicates,
And sodium carbonate;
(e) retarding solvent, such as paraffin;
(f) absorbsion accelerator, for example, quaternary ammonium compound;
(g) wetting agent, such as cetanol and glycerin monostearate;
(h) adsorbent, for example, kaolin;With
(i) lubricant, for example, talcum, calcium stearate, magnesium stearate, solid polyethylene glycol, lauryl sodium sulfate, or
Its mixture.In capsule, tablet and pill, dosage form also may include buffer.
Coating and shell material preparation also can be used in the solid dosage forms, such as casing and other materials well known in the art.It
May include opacifying agent, also, in this composition active constituent release can in a delayed fashion it is in the digestive tract certain
It is discharged in a part.The example of adoptable embedding component is polymeric material and wax material.
Liquid formulation for oral administration includes pharmaceutically acceptable lotion, solution, suspension, syrup or tincture.
Other than active constituent, liquid dosage form may include the inert diluent routinely used in this field, such as water or other solvents, solubilising
Agent and emulsifier, example know, ethyl alcohol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-BDO, dimethylformamide
And oil, the especially mixture of cottonseed oil, peanut oil, maize germ, olive oil, castor oil and sesame oil or these substances
Deng.Other than these inert diluents, composition also may include auxiliary agent, such as wetting agent, emulsifier and suspending agent, sweetener, rectify
Taste agent and fragrance.
Other than active constituent, suspension may include suspending agent, for example, ethoxylation isooctadecane alcohol, polyoxyethylene mountain
The pure and mild Isosorbide Dinitrate of pears, microcrystalline cellulose, aluminium methoxide and agar or the mixture of these substances etc..
Composition for parenteral injection may include physiologically acceptable sterile, aqueous or anhydrous solution, dispersion liquid,
Suspension or lotion, and the aseptic powdery for re-dissolving into sterile Injectable solution or dispersion liquid.It is suitable aqueous and
Nonaqueous carrier, diluent, solvent or excipient include water, ethyl alcohol, polyalcohol and its suitable mixture.
The compounds of this invention can be administered alone, or be administered in combination with other treatment drug (such as antidiabetic drug).
It is that the compounds of this invention of safe and effective amount is applied to mammal in need for the treatment of when using pharmaceutical composition
(such as people), wherein dosage is the effective dosage pharmaceutically thought when application, for the people of 60kg weight, day is to medicament
Amount is usually 1~2000mg, preferably 20~500mg.Certainly, specific dosage is also contemplated that administration route, patient health situation etc.
Factor, within the scope of these are all skilled practitioners technical ability.
Drug combination: compound of formula I can be combined to the known other medicines for treating or improving similar symptom.Combine to
When medicine, originally the administration mode of drug and dosage are remained unchanged, and subsequently or simultaneously take compound of formula I.When compound of formula I with
Other one or more drugs are simultaneously, it is preferable to use simultaneously containing one or more of known drugs and compound of formula I when taking
Pharmaceutical composition.The period that drug combination is also included within overlapping takes compound of formula I and other one or more of known drugs.
When Formulas I compound and other one or more of drugs carry out drug combination, the dosage of compound of formula I or known drug may
Dosage when than their independent medications is lower.
The drug of drug combination can be carried out with compound of formula I or active constituent includes but is not limited to:
Estrogenic agents, androgen receptor modifier, retinoid-like receptor modulators, cytotoxin/cell suppression
Preparation, antiproliferative, protein transferase inhibitor, HMG-CoA reductase inhibitor, HIV kinases inhibitor, reverse transcriptase
Inhibitor, angiogenesis inhibitors, cell Proliferation and survival signaling inhibitor interfere the drug of cell cycle chechpoint and cell to wither
Die inducer, cytotoxic drug, tyrosine protein inhibitor, EGFR inhibitor, VEGFR inhibitor, serine/threonine egg
White inhibitor, Bcr-Abl inhibitor, c-Kit inhibitor, Met inhibitor, Raf inhibitor, mek inhibitor, MMP inhibitor,
Topoisomerase enzyme inhibitor, Histone deacetylase inhibitor, proteasome inhibitor, CDK inhibitor, Bcl-2 family egg
White inhibitor, MDM2 family protein inhibitor, IAP family protein inhibitor, STAT family protein inhibitor, PI3K inhibitor,
AKT inhibitor, integrin retarding agent, interferon-' alpha ', IL-12, cox 2 inhibitor, p53, p53 activator, VEGF are anti-
Body, EGF antibody etc..
In one embodiment, the drug of drug combination can be carried out with compound of formula I or active constituent includes but not
Limitation are as follows: Aldesleukin, alendronic acid, interferon, Ah Qu Nuoying, Allopurinol, allopurinol sodium, palonosetron hydrochloride,
Hemel, amino glutethimide, Amifostine, Amrubicin, amphidine, arimidex, Dolasetron, aranesp,
Arglabin, arsenic trioxide, A Nuoxin, U-18496, imuran, BCG vaccine or tice BCG vaccine, bestatin, acetic acid times
Ta meter Song, betamethasone sodium phosphate preparation, bexarotene, Bleomycin Sulphate, broxuridine, bortezomib, busulfan, drop calcium
Element, A Laizuo monoclonal antibody injection, capecitabine, carboplatin, Kang Shi get, cefesone, Celmoleukin, daunorubicin, benzenebutanoic acid
Mustargen, cis-platinum, Cladribine, Cladribine, chlorine bend phosphoric acid, cyclophosphamide, arabinose born of the same parents' former times, Dacarbazine, actinomycin D, soft
Erythromycin liposome, dexamethasone, dexamethasone phosphate, Estradiol Valerate, denileukin diftitox, Di Bomei, Deslorelin,
La Zuosheng, diethylstilbestrol, Fluconazole, docetaxel, doxifluridine, adriamycin, Dronabinol, -166- chitosan of admiring are compound
Object, eligard, rasburicase, epirubicin hydrochloride, aprepitant, Epi-ADM, Epoetin Alfa, erythropoietin(EPO), according to
Platinum, Ergamisole, estradiol preparation, 17-β-estradiol, estramustine phosphate sodium, ethinyloestradiol, Amifostine, hydroxyl phosphoric acid, it is all finish
Again, etoposide, Fadrozole, tamoxifen preparation, Filgrastim, Tamsulosin, Fei Leisi are replaced, floxuridine, Fluconazole, fluorine reach
Draw shore, 5- fluorodeoxyuridine monophosphate, 5 FU 5 fluorouracil, Fluoxymesterone, Flutamide, formestane, 1- β-D- Ah
Sugared furanose born of the same parents thialdine -5 '-stearoyl phosphate, Fotemustine, fulvestrant, gamma globulin, gemcitabine, lucky appropriate list
Anti-, imatinib mesylate, Gliadel, Goserelin, Graniseeron Hydrochloride, Histrelin, He Meixin,
Hydrocortisone, erythro-hydroxynonyl adenine, replace smooth different shellfish Mo Dankang, idarubicin, ifosfamide, interference at hydroxycarbamide
Plain α, interferon-' alpha ' 2, interferon α-2 A, interferon α-2 B, Interferon α-nl, Alferon N, interferon beta, interferon gamma-
La, interleukin 2, intron A, Iressa, Irinotecan, Kytril, sulfuric acid lentinan, Letrozole, Calcium Folinate-SF leaf
Acid, Leuprorelin, leuprolide acetate, L-tetramisole, levo leucovorin calcium salt, levothyroxine sodium, Levothyroxine
Preparation of sodium, lomustine, Lonidamine, Dronabinol, mustargen, Mecobalamin, medroxyprogesterone acetate, megestrol acetate, beauty
Method logical sequence, esterified estriol, 6- coloured glaze base purine, mesna, amethopterin, amino-laevulic acid methyl esters, Miltefosine, happiness are mould
Element, mitomycin C, mitotane, rice support green onion quinone, Trilostane, citric acid Evacet, Nedaplatin, Pegylation are non-
Geseting, oprelvekin, neupogen, Nilutamide, tamoxifen, NSC-631570, recombination human interleukins-11-
β, Octreotide, Ondansetron Hydrochloride, dehydrohydro-cortisone oral solution, oxaliplatin, taxol, prednisone sodium phosphate system
Agent, Pegaspargase, PEG-IFN alpha-2a, Pentostatin, Picibanil, hydrochloric acid pilocarpine, adjoin it is soft than star, plicamycin, porphines nurse
Sodium, prednimustine, Prednisolone Steaglate, prednisone, premarin, the third kappa navel, epoetin, thunder are for song
Plug, Libiee, Etidronic Acid rhenium -186, Mabthera, Redoxon-A, Romurtide, Salagen, Octreotide, Sha Mo
Department's pavilion, sizofiran, Sobuzoxane, bluffs sodium methylprednisolone, Paphos acid, stem-cell therapy, streptozotocin, strontium chloride-at Semustine
89, levoid, tamoxifen, tansulosin, Ta Suonaming, tastolactone, taxotere, teceleukin, replace
Muzolimine, Teniposide, testosterone propionate, methyltestosterone, thioguanine, thio-tepa, thyrotropic hormone, Tiludronic Acid, topology are replaced
Health, Toremifene, tositumomab, Herceptin, Treosulfan, Tretinoin, methopterin tablet, trimethyl melamine, front three
Qu Sha, acetic acid Triptorelin, triptorelin pamoate, excellent fudding, uridine, valrubicin, Vesnarinone, vincaleukoblastinum, Changchun
New alkali, Vindesine, vinorelbine, virulizin, dextropine imine, Zinostatin stimalamer, ondansetron, Taxol-protein are steady
Customization agent, acolbifene, interferon r-lb, affinitak, aminopterin-induced syndrome, arzoxifene, asoprisnil, atamestane,
Atrasentan, BAY43-9006, Avastin, CCI-779, CDC-501, Celebrex, Cetuximab, crisnatol, cyclopropyl
Progesterone acetate, Decitabine, DN-101, adriamycin-MTC, dSLIM, dutasteride, edotecarin, Eflornithine, according to
Health, Suwei A amine, histamine dihydrochloric acid, Histrelin hydrogel implant, holmium -166DOTMP, ibandronic acid, interferon are replaced in happiness
γ, introne-PEG, ixabepilone, keyhole shape hemocyanin, L-651582, lanreotide, lasofoxifene, libra,
Lonafamib, Miproxifene, minot bend acid esters, MS-209, liposome MTP-PE, MX-6, nafarelin, Nemorubicin, new
It cuts down and takes charge of he, Nola Qu Te, oblimersen, onco-TCS, osidem, taxol polyglutamic acid esters, pamidronate disodium injection, PN-401, QS-
21, overstate the West, R-1549, Raloxifene, ranpirnase, isotretinoin, Satraplatin, seocalcitol, T-138067, tarceva,
Docosahexaenoic acid taxol, extrasin alpha l, loud, high-pitched sound azoles furan woods, tipifarnib, Tirapazamine, TLK-286, Toremifene,
Trans- MID-lo7R, valspodar, Vapreotide, vatalanib, Verteporfin, vinflunine, Z-100 and azoles come unicorn acid or it
Combination.
The invention has the beneficial effects that:
(1) a kind of 2- amino-metadiazine compound of structure novel is provided.
(2) such compound can effectively inhibit the effect of EGFR protein kinase drug resistant mutants, can be used for preparing anti-swollen
Tumor medicine.
(3) such compound can overcome existing drug Gefitinib, Tarceva especially Osimertinib
(AZD9291) etc. the drug resistance of inductions has selectivity to Wild type EGFR, has good pharmacokinetic property.
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory
Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.Unless otherwise stated, otherwise percentage and
Number is calculated by weight.
Unless otherwise defined, all professional and scientific terms as used herein and meaning familiar to those skilled in the art
Justice is identical.In addition, any method similar to or equal to what is recorded and material can be applied to the method for the present invention.Wen Zhong
The preferred implement methods and materials are for illustrative purposes only.
Embodiment 1
(((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- trifluoromethyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus (LS2-31)
Synthetic route is as follows:
The preparation of step 1. (2- aminophenyl) dimethyl phosphorus (2)
By adjacent Iodoaniline (1,5.06g, 23mmol), dimethyl phosphorus (2.20g, 27.2mmol), palladium acetate (0.26g,
1.2 mmol), the bis- diphenylphosphine -9,9- xanthphos (0.67g, 1.2mmol) of 4,5- and potassium phosphate (5.40g,
It 25.4mmol) is dissolved in 50 milliliters of n,N-Dimethylformamide solvents, argon gas protection, overnight in 120 degrees Celsius of reactions.To anti-
Should completely, decompression is spin-dried for most of solvent, three times with methylene chloride/water extraction, merges organic layer, organic layer saturated salt solution
It washes, then is spin-dried for after being dried with anhydrous sodium sulfate, obtain solid 3.2g, yield 82% through column chromatography for separation.
1H NMR(400MHz,DMSO-d6)δ7.26-7.13(m,2H),6.68-6.61(m,1H),6.59-6.52(m,
1H), 6.14 (s, 2H), 1.64 (d, J=13.2Hz, 6H)
MS(ESI):m/z 170[M+H]+.
The preparation of step 2. (2- ((2,5- dichloro pyrimidine -4- base) amino) phenyl) dimethyl phosphorus (3)
By 2,4,5- trichloropyrimidine (2.70g, 14.6mmol), (2- aminophenyl) dimethyl phosphorus (2,2.47g,
14.6mmol), potassium carbonate (2.42g, 17.5mmol), tetra-n-butyl ammonium sulfate (0.5g, 1.46mmol) are dissolved in 20 milliliters of N, N-
In solvent dimethylformamide, overnight in 65 degrees Celsius of reactions.It three times with methylene chloride/water extraction is associated with to fully reacting
Machine layer, organic layer are washed with saturated common salt, then are spin-dried for after being dried with anhydrous sodium sulfate, obtain solid 3.8g through column chromatography for separation, are received
Rate 84%.
1H NMR(400MHz,DMSO-d6) δ 11.83 (s, 1H), 8.46 (s, 1H), 8.43 (dd, J=8.3Hz, 4.2Hz,
1H), 7.71-7.56(m,2H),7.31-7.21(m,1H),1.83(s,3H),1.80(s,3H).
MS(ESI):m/z 316[M+H]+.
The preparation of step 3.1- methyl -4- (1- (4- nitro -2- benzotrifluoride) piperidin-4-yl) piperazine (5)
By 2- fluoro-5-nitro trifluor toluene (0.5g, 2.4mmol), 1- methyl -4- (piperidin-4-yl) piperazine hydrochloride
(0.64g, 2.87 mmol), potassium carbonate (0.67g, 4.8mmol) are dissolved in 15 milliliters of acetonitrile solvents, are heated to 80 degrees Celsius instead
It should stay overnight.Three times with methylene chloride/water extraction merge organic layer, organic layer is washed with saturated common salt, then is used to fully reacting
It is spin-dried for after anhydrous sodium sulfate is dry, obtains solid 0.84g, yield 93% through column chromatography for separation.
1H NMR(400MHz,DMSO-d6) δ 8.41-8.32 (m, 2H), 7.49 (d, J=8.7Hz, 1H), 3.35 (s, 2H),
2.93 (s, 2H), 2.53-2.17 (m, 9H), 2.14 (s, 3H), 1.87 (d, J=11.4Hz, 2H), 1.62-1.44 (m, 2H)
MS(ESI):m/z 373[M+H]+.
The preparation of step 4.4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- (trifluoromethyl) aniline (6)
To the first of 1- methyl -4- (1- (4- nitro -2- benzotrifluoride) piperidin-4-yl) piperazine (5,0.84g, 2.23mmol)
10% palladium carbon of catalytic amount is added in alcohol, tetrahydrofuran mixed solvent (each 10 milliliters), reacts at room temperature 3 hours under an atmosphere of hydrogen.
To fully reacting, suction filtered through kieselguhr is spin-dried for, and obtains solid 0.72g, yield 95% through column chromatography for separation.
1H NMR(400MHz,DMSO-d6) δ 7.19 (d, J=8.5Hz, 1H), 6.80 (d, J=2.6Hz, 1H), 6.78-
(6.69 m, 1H), 5.31 (s, 2H), 2.81 (d, J=11.3Hz, 2H), 2.64 (t, J=10.8Hz, 2H), 2.55-2.40 (m,
4H), 2.40-2.16 (m, 5H), 2.14 (s, 3H), 1.76 (d, J=11.0Hz, 2H), 1.52-1.41 (m, 2H)
MS(ESI):m/z 343[M+H]+.
Step 5. (2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- trifluoromethyl)
Amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus (LS2-31) preparation
Into 15 milliliters of tube sealings be added (2- ((2,5- dichloro pyrimidine -4- base) amino) phenyl) dimethyl phosphorus (3,
0.1g, 0.32 mmol), 4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- (trifluoromethyl) aniline (6,0.1g,
0.29mmol), the ethanol solution and 3 milliliters of glycol monoethyl ethers of 0.3 milliliter of 2.5M HCl, is heated to 120 degrees Celsius and reacted
Night.To fully reacting, after being spin-dried for most of solvent, three times with methylene chloride/water extraction, merge organic layer, organic layer saturation
Salt washing, then be spin-dried for after being dried with anhydrous sodium sulfate, solid 0.12g, yield 71% are obtained through column chromatography for separation.
1H NMR(400MHz,CDCl3)δ10.96(s,1H),8.53(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.10
(s, 1H), 7.75 (d, J=2.5Hz, 1H), 7.67 (dd, J1=8.6Hz, J2=2.4Hz, 1H), 7.45 (t, J=7.9Hz,
1H), 7.33-7.27 (m, 2H), 7.16-7.08 (m, 1H), 6.96 (s, 1H), 3.07 (d, J=11.4Hz, 2H), 2.86-
2.31(m,11H), 2.30(s,3H),1.98-1.87(m,2H),1.85(s,3H),1.82(s,3H),1.78-1.70(m,
2H).
MS(ESI):m/z 622[M+H]+.
Embodiment 2
(2- ((the chloro- 2- of 5- ((5- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus (LS2-39)
Synthetic method is referring to embodiment 1, yield 67%.
1H NMR(400MHz,CDCl3) δ 8.45-8.35 (m, 1H), 8.18 (d, J=2.5Hz, 1H), 8.08 (s, 1H),
7.84 (d, J=2.5Hz, 1H), 7.62 (ddd, J1=14.1Hz, J2=7.7Hz, J3=1.4Hz, 1H), 7.54 (t, J=
7.9Hz, 1H), 7.32-7.20 (m, 1H), 3.39 (d, J=12.4Hz, 2H), 3.09-2.65 (m, 9H), 2.64-2.32 (m,
5H),2.22(s,3H), 2.08-1.93(m,2H),1.87(s,3H),1.83(s,3H),1.76-1.65(m,2H).
MS(ESI):m/z 569[M+H]+.
Embodiment 3
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus (LS2-40)
Synthetic method is referring to embodiment 1, yield 58%.
1H NMR(400MHz,CDCl3)δ10.94(s,1H),8.58(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.08
(s, 1H), 7.76 (d, J=2.5Hz, 1H), 7.55 (t, J=7.9Hz, 1H), 7.33-7.28 (m, 1H), 7.21 (dd, J1=
8.6Hz,J2=2.5Hz, 1H), 7.16-7.08 (m, 1H), 6.98 (d, J=8.7Hz, 1H), 6.84 (s, 1H), 3.40 (d, J
=11.7Hz, 2H), 2.84-2.46 (m, 9H), 2.46-2.37 (s, 1H), 2.33 (s, 3H), 2.05-1.89 (m, 3H), 1.84
(d, J=13.1Hz, 6H), 1.81-1.73 (m, 2H)
MS(ESI):m/z 588[M+H]+.
Embodiment 4
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus (LS2-43)
Synthetic method is referring to embodiment 1, yield 61%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.62(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.44 (t, J=7.9Hz, 1H), 7.36-7.27 (m, 3H), 7.14-7.05 (m, 1H), 6.96 (d, J=8.4Hz,
1H), 6.80 (s, 1H), 3.14 (d, J=11.9Hz, 2H), 2.86-2.38 (m, 10H), 2.37-2.29 (m, 4H), 2.27 (s,
3H), 2.00-1.90 (m, 2H), 1.83 (d, J=13.1Hz, 6H), 1.78-1.69 (m, 2H)
MS(ESI):m/z 568[M+H]+.
Embodiment 5
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus (LS2-71)
Synthetic method is referring to embodiment 1, yield 53%.
1H NMR(400MHz,CDCl3)δ10.90(s,1H),8.62(dd,J1=8.0Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.48-7.39 (m, 1H), 7.37-7.26 (m, 3H), 7.15-7.06 (m, 1H), 7.01 (d, J=8.4Hz, 1H),
6.87 (s, 1H), 2.93 (t, J=4.7Hz, 4H), 2.78-2.44 (m, 4H), 2.37 (s, 3H), 2.28 (s, 3H), 1.83 (d,
J=13.2Hz, 6H)
MS(ESI):m/z 485[M+H]+.
Embodiment 6
(2- ((the chloro- 2- of 5- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -3- aminomethyl phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus (LS2-73)
Synthetic method is referring to embodiment 1, yield 68%.
1H NMR(400MHz,CDCl3)δ10.88(s,1H),8.61(dd,J1=8.0Hz, J2=4.2Hz, 1H), 8.06
(s, 1H), 7.44 (t, J=7.6Hz, 1H), 7.38-7.20 (m, 3H), 7.18-7.05 (m, 2H), 7.01 (d, J=8.4Hz,
1H), 3.10 (t, J=6.8Hz, 2H), 2.73-2.53 (m, 5H), 2.37 (s, 6H), 2.26 (s, 3H), 1.82 (d, J=
12.4Hz,6H).
MS(ESI):m/z 487[M+H]+.
Embodiment 7
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3aR, 6aS) -5- methyl hexahydropyrrolo [3,4-c] pyrroles -2 (1H)-yl)
Phenyl) amino) pyrimidine -4- base) amino) phenyl) dimethyl phosphorus (LS2-75)
Synthetic method is referring to embodiment 1, yield 56%.
1H NMR(400MHz,CDCl3)δ10.90(s,1H),8.63(dd,J1=8.0Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.48-7.42 (m, 1H), 7.35-7.27 (m, 3H), 7.16-7.06 (m, 1H), 6.94 (d, J=8.4Hz, 1H),
6.77 (s, 1H), 3.13-2.78 (m, 8H), 2.45-2.22 (m, 8H), 1.83 (d, J=13.2Hz, 6H)
MS(ESI):m/z 511[M+H]+.
Embodiment 8
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methyl-1,4- phenodiazine heptane -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus (LS2-77)
Synthetic method is referring to embodiment 1, yield 47%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.63(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H),7.48-7.39(m,1H),7.33-7.26(m,3H),7.13-7.06(m,1H),7.07-6.98(m,1H),6.88
(s,1H), 3.23-3.10(m,4H),2.82-2.70(m,4H),2.43(s,3H),2.29(s,3H),2.02-1.95(m,
2H), 1.83 (d, J=13.2Hz, 6H)
MS(ESI):m/z 499[M+H]+.
Embodiment 9
(((the chloro- 2- of 5- ((3- methoxyl group -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus (LS2-80)
Synthetic method is referring to embodiment 1, yield 66%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.61(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.41 (t, J=7.8Hz, 1H), 7.32-7.22 (m, 1H), 7.13-6.96 (m, 4H), 6.87 (d, J=8.5Hz,
1H), 3.74 (s, 3H), 3.51 (t, J=16.4Hz, 2H), 2.73-2.35 (m, 10H), 2.33-2.08 (m, 5H), 1.90-
1.76(m,9H).
MS(ESI):m/z 584[M+H]+.
Embodiment 10
(2- ((the chloro- 2- of 5- ((4- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus (LS2-83)
Synthetic method is referring to embodiment 1, yield 68%.
MS(ESI):m/z 569[M+H]+.
Embodiment 11
(2- ((the chloro- 2- of 5- ((3- methyl -4- (9- methyl -3,9- phenodiazine spiral shell [5.5] hendecane -3- base) phenyl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus (LS2-86)
Synthetic method is referring to embodiment 1, yield 52%.
1H NMR(400MHz,CDCl3)δ10.88(s,1H),8.63(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.44 (t, J=7.8Hz, 1H), 7.35-7.21 (m, 3H), 7.15-7.06 (m, 1H), 6.98 (d, J=8.2Hz,
1H), 6.87 (s, 1H), 2.81 (t, J=5.2Hz, 4H), 2.52-2.36 (m, 4H), 2.27 (d, J=15.6Hz, 6H),
1.98-1.77(m,10H), 1.70-1.60(m,4H).
MS(ESI):m/z 553[M+H]+.
Embodiment 12
(((the chloro- 2- of 5- ((3- methyl -4- (7- methyl -2,7- phenodiazine spiral shell [3.5] nonane -2- base) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus (LS2-94)
Synthetic method is referring to embodiment 1, yield 60%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.64(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.04
(d, J=5.1Hz, 1H), 7.48-7.40 (m, 1H), 7.32-7.22 (m, 2H), 7.18 (dd, J1=8.5Hz, J2=2.4Hz,
1H),7.11 (td,J1=7.5Hz, J2=1.3Hz, 1H), 6.80 (s, 1H), 6.50 (d, J=8.4Hz, 1H), 3.99-3.76
(m, 5H), 3.52 (d, J=20.0Hz, 4H), 2.51-2.38 (m, 2H), 2.19 (s, 3H), 2.07-1.86 (m, 4H), 1.83
(d, J=13.2Hz, 6H)
MS(ESI):m/z 526[M+H]+.
Embodiment 13
(S)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus (LS2-95)
Synthetic method is referring to embodiment 1, yield 48%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.62(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.44 (t, J=7.2Hz, 1H), 7.36-7.21 (m, 3H), 7.14-7.04 (m, 1H), 6.99 (d, J=8.5Hz,
1H), 6.86 (s, 1H), 3.04-2.82 (m, 4H), 2.61-2.43 (m, 2H), 2.41-2.24 (m, 7H), 1.83 (d, J=
13.2Hz, 6H), 1.11 (d, J=6.4Hz, 3H)
MS(ESI):m/z 499[M+H]+.
Embodiment 14
(R)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus (LS2-96)
Synthetic method is referring to embodiment 1, yield 51%.
1H NMR(400MHz,CDCl3)δ10.90(s,1H),8.62(dd,J1=8.2Hz, J2=4.2Hz, 1H), 8.07
(s, 1H), 7.48-7.40 (m, 1H), 7.36-7.22 (m, 3H), 7.15-7.05 (m, 1H), 6.99 (d, J=8.4Hz, 1H),
6.83 (s, 1H), 3.06-2.80 (m, 4H), 2.60-2.42 (m, 2H), 2.42-2.16 (m, 7H), 1.83 (d, J=13.2Hz,
6H), 1.11 (d, J=6.4 Hz, 3H)
MS(ESI):m/z 499[M+H]+.
Embodiment 15
(2- ((the chloro- 2- of 5- ((5- ((2- (dimethylamino) ethyl) (methyl) amino) -6- picoline -2- base) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus (LS2-97)
Synthetic method is referring to embodiment 1, yield 55%.
1H NMR(400MHz,CDCl3) δ 10.99 (s, 1H), 8.61-8.46 (m, 1H), 8.02 (s, 1H), 7.53 (d, J=
8.8 Hz,1H),7.33-7.25(m,1H),7.21(dd,J1=14.4Hz, J2=7.6Hz, 1H), 7.03 (t, J=6.8Hz,
1H), 6.37 (s, 1H), 6.35 (s, 1H), 3.78-3.65 (m, 2H), 3.07 (s, 3H), 2.53 (t, J=7.2Hz, 2H),
2.35 (s, 3H), 2.33 (s, 6H), 1.82 (d, J=13.2Hz, 6H)
MS(ESI):m/z 488[M+H]+.
Embodiment 16
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3R, 5S) -3,4,5- tri methyl piperazine -1- base) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus (LS2-99)
Synthetic method is referring to embodiment 1, yield 46%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.62(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.48-7.40 (m, 1H), 7.36-7.23 (m, 3H), 7.17-7.04 (m, 1H), 6.96 (d, J=8.4Hz, 1H),
6.84(s,1H), 2.92(dd,J1=8.7Hz, J2=2.4Hz, 2H), 2.58 (t, J=10.4Hz, 2H), 2.49-2.38 (m,
2H), 2.34 (s, 3H), 2.28 (s, 3H), 1.83 (d, J=13.2Hz, 6H), 1.14 (d, J=6.0Hz, 6H)
MS(ESI):m/z 513[M+H]+.
Embodiment 17
(2- ((the chloro- 2- of 5- ((1- (2- (diethylamino) ethyl) -1H- pyrazoles -4- base) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus (LS2-100)
Synthetic method is referring to embodiment 1, yield 69%.
1H NMR(400MHz,CDCl3)δ10.81(s,1H),8.54(dd,J1=7.6Hz, J2=4.0Hz, 1H), 8.08
(s, 1H),7.76(s,1H),7.57-7.45(m,2H),7.34-7.27(m,1H),7.15-7.07(m,1H),6.66(s,
1H), 4.12 (t, J=6.8Hz, 2H), 2.87 (t, J=7.2Hz, 2H), 2.54 (q, J=7.2Hz, 4H), 1.83 (d, J=
13.2Hz, 6H), 0.99 (t, J=7.2Hz, 6H)
MS(ESI):m/z 462[M+H]+.
Embodiment 18
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (oxetanes -3- base) piperazine -1- base) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus (LS2-87)
Synthetic method is referring to embodiment 1, yield 40%.
1H NMR(400MHz,CDCl3)δ10.90(s,1H),8.61(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.44 (t, J=7.2Hz, 1H), 7.36 (dd, J1=8.4Hz, J2=2.4Hz, 1H), 7.33-7.22 (m, 2H),
7.18-7.05 (m,1H),6.98-6.87(m,2H),4.19(m,1H),4.00-3.83(m,2H),3.00-2.79(m,8H),
2.68 (s, 2H), 2.26 (s, 3H), 1.83 (d, J=13.2Hz, 6H)
MS(ESI):m/z 527[M+H]+.
Embodiment 19
(2- ((the chloro- 2- of 5- ((5- (piperazine -1- ylmethyl) pyridine -2- base) amino) pyrimidine-4-yl) amino) phenyl) two
Methyl oxidation phosphorus (LS2-101)
Synthetic method is referring to embodiment 1, yield 53%.
1H NMR(400MHz,CDCl3)δ10.74(s,1H),8.56(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.01
(s, 1H), 7.96 (d, J=2.0Hz, 1H), 7.54-7.41 (m, 2H), 7.32-7.21 (m, 2H), 7.13-7.02 (m, 1H),
6.50 (d, J=8.4Hz, 1H), 4.48 (s, 2H), 3.74 (t, J=5.2Hz, 4H), 2.47 (t, J=5.2Hz, 4H), 1.82
(d, J=13.2Hz, 6H)
MS(ESI):m/z 472[M+H]+.
Embodiment 20
(2- ((the chloro- 2- of 5- ((3- methoxyl group -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus (LS2-102)
Synthetic method is referring to embodiment 1, yield 66%.
1H NMR(400MHz,CDCl3)δ10.88(s,1H),8.60(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.06
(s, 1H), 7.39 (t, J=7.6Hz, 1H), 7.29-7.18 (m, 2H), 7.12-6.99 (m, 3H), 6.92-6.82 (m, 1H),
3.74 (s, 3H), 3.29-2.79 (m, 4H), 2.76-2.47 (m, 4H), 2.35 (s, 3H), 1.81 (d, J=13.2Hz, 6H)
MS(ESI):m/z 501[M+H]+.
Embodiment 21
(2- ((the chloro- 2- of 5- ((4- (4- ethyl piperazidine -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus (LS2-104)
Synthetic method is referring to embodiment 1, yield 70%.
1H NMR(400MHz,CDCl3)δ10.91(s,1H),8.63(dd,J1=8.0Hz, J2=4.4Hz, 1H), 8.07
(s, 1H),7.46-7.40(m,1H),7.35(dd,J1=8.4Hz, J2=2.4Hz, 1H), 7.29 (d, J=2.9Hz, 1H),
7.28-7.22 (m, 1H), 7.15-7.05 (m, 1H), 7.01 (d, J=8.4Hz, 1H), 6.82 (s, 1H), 2.95 (t, J=
4.8Hz, 4H), 2.76-2.52 (m, 4H), 2.50 (q, J=7.2Hz, 2H), 2.29 (s, 3H), 1.83 (d, J=13.2Hz,
6H), 1.14 (t, J=7.2 Hz, 3H)
MS(ESI):m/z 499[M+H]+.
Embodiment 22
(2- ((2- ((the bromo- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) -5- chlorine pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus (LS2-106)
Synthetic method is referring to embodiment 1, yield 60%.
1H NMR(400MHz,CDCl3)δ10.85(s,1H),8.54(dd,J1=8.0Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.87 (d, J=2.8Hz, 1H), 7.60-7.49 (m, 1H), 7.33 (dd, J1=8.8Hz, J2=2.4Hz, 1H),
7.31-7.23 (m,1H),7.17-7.07(m,1H),7.06-6.98(m,2H),3.04(s,4H),2.62(s,4H),2.37
(s, 3H), 1.83 (d, J=13.2Hz, 6H)
MS(ESI):m/z 549[M+H]+.
Embodiment 23
(2- ((2- ((the bromo- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- chlorine pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus (LS2-108)
Synthetic method is referring to embodiment 1, yield 55%.
1H NMR(400MHz,CDCl3)δ10.95(s,1H),8.58(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.08
(s, 1H), 7.89 (d, J=2.8Hz, 1H), 7.60-7.51 (m, 1H), 7.35-7.24 (m, 2H), 7.16-7.09 (m, 1H),
6.98 (d, J=8.4Hz, 1H), 6.85 (s, 1H), 3.37 (d, J=11.6Hz, 2H), 2.81-2.33 (m, 11H), 2.30 (s,
3H),1.98-1.88(m, 2H),1.87-1.73(m,8H).
MS(ESI):m/z 632[M+H]+.
Embodiment 24
(2- ((the chloro- 2- of 5- ((6- methyl -5- (4- methylpiperazine-1-yl) pyridine 2- yl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 486[M+H]+.
Embodiment 25
(2- ((5- chlorine 2- ((3- methyl -4- (piperidin-4-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl
Phosphorous oxide
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 470[M+H]+.
Embodiment 26
(2- ((the chloro- 2- of 5- ((4- (4- (dimethylamino) piperidin-1-yl) -3- aminomethyl phenyl) amino) pyrimidine 4- yl) ammonia
Base) phenyl) dimethyl phosphorus (LS2-116)
Synthetic method is referring to embodiment 1, yield 70%.
1H NMR(400MHz,CDCl3)δ10.89(s,1H),8.62(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.44 (t, J=8.4Hz, 1H), 7.34-7.22 (m, 3H), 7.14-7.07 (m, 1H), 6.99-6.90 (m, 2H),
3.15 (d, J=12.4Hz, 2H), 2.65 (t, J=10.4Hz, 2H), 2.49-2.44 (m, 1H), 2.42 (s, 6H), 2.27 (s,
3H), 2.04-1.91 (m, 2H), 1.83 (d, J=13.2Hz, 6H), 1.79-1.67 (m, 2H).
MS(ESI):m/z 513[M+H]+.
Embodiment 27
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus (LS2-114)
Synthetic method is referring to embodiment 1, yield 69%.
1H NMR(400MHz,CDCl3)δ10.92(s,1H),8.56(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.07
(s, 1H), 7.74 (d, J=2.8Hz, 1H), 7.52 (t, J=7.6Hz, 1H), 7.33-7.18 (m, 3H), 7.15-7.06 (m,
1H), 7.00 (d, J=8.4Hz, 1H), 3.05 (s, 4H), 2.63 (s, 4H), 2.37 (s, 3H), 1.83 (d, J=13.2Hz,
6H)。
MS(ESI):m/z 505[M+H]+。
Embodiment 28
(2- ((the chloro- 2- of 5- ((4- (4- methylpiperazine-1-yl) -3- trifluoromethyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus (LS2-113)
Synthetic method is referring to embodiment 1, yield 73%.
1H NMR(400MHz,CDCl3)δ10.96(s,1H),8.52(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.11
(s, 1H), 7.77-7.69 (m, 2H), 7.45 (t, J=7.2Hz, 1H), 7.35 (d, J=9.6Hz, 1H), 7.32-7.25 (m,
1H), 7.16-7.09 (m, 1H), 7.05 (s, 1H), 2.94 (t, J=4.8Hz, 4H), 2.57 (s, 4H), 2.36 (s, 3H),
1.84 (d, J=13.2 Hz, 6H).
MS(ESI):m/z 539[M+H]+。
Embodiment 29
(2- ((the chloro- 2- of 5- ((the fluoro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus (LS2-70)
Synthetic method is referring to embodiment 1, yield 71%.
1H NMR(400MHz,CDCl3)δ10.90(s,1H),8.55(dd,J1=8.4Hz, J2=4.4Hz, 1H), 8.09
(s, 1H),7.58(dd,J1=14.8Hz, J2=2.8Hz, 1H), 7.52 (d, J=8.4Hz, 1H), 7.35-7.27 (m, 1H),
7.19-7.09 (m, 1H), 7.05-6.99 (m, 1H), 6.95 (s, 1H), 6.90 (t, J=8.8Hz, 1H), 3.14 (s, 4H),
2.72 (s, 4H), 2.43 (s, 3H), 1.83 (d, J=12.8Hz, 6H)
MS(ESI):m/z 489[M+H]+.
Embodiment 30
(2- ((the chloro- 2- of 5- ((the chloro- 4- morpholino phenyl of 3-) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 492[M+H]+.
Embodiment 31
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2- base)
Phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 517[M+H]+.
Embodiment 32
1- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) benzene
Base) piperazine -1- base) ethyl -1- ketone
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 533[M+H]+.
Embodiment 33
2- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) benzene
Base) piperazine -1- base)-N- methylacetamide
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 562[M+H]+.
Embodiment 34
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (2- ethoxy) piperazine -1- base) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 535[M+H]+.
Embodiment 35
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 533[M+H]+.
Embodiment 36
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- hydroxy piperidine -1- base) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 506[M+H]+.
Embodiment 37
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 533[M+H]+.
Embodiment 38
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 519[M+H]+.
Embodiment 39
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) heterocyclic butane -1- base) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 505[M+H]+.
Embodiment 40
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (methyl (2- (methylamino) ethyl) amino) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 493[M+H]+.
Embodiment 41
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (cyclopropyl alkyl methyl) piperazine -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 545[M+H]+.
Embodiment 42
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2-
Base) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 600[M+H]+.
Embodiment 43
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- morpholinyl piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 575[M+H]+.
Embodiment 44
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methyl-1,4- diaza heptane -1- base) piperidin-1-yl) phenyl) ammonia
Base) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 602[M+H]+.
Embodiment 45
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (piperidin-1-yl) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 559[M+H]+.
Embodiment 46
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (pyrrolidin-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 559[M+H]+.
Embodiment 47
(((2- ((4- (4- (azetidine -1- ylmethyl) piperidin-1-yl) -3- chlorphenyl) amino) -5- chlorine is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 559[M+H]+.
Embodiment 48
(2- ((2- ((4- ([bis- piperidines of 1,4'-] -1'- base) -3- chlorphenyl) amino) -5- chlorine pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 573[M+H]+.
Embodiment 49
(2- ((the chloro- 2- of 5- ((3- chlorine 4- (3- (pyrrolidin-1-yl) propoxyl group) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 534[M+H]+.
Embodiment 50
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methylpyrrolidin- 3- yl) oxygroup) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 506[M+H]+.
Embodiment 51
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methyl piperidine -4- base) oxygroup) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 520[M+H]+.
Embodiment 52
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (1- (piperidin-4-yl) -1H- pyrazoles -4- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 556[M+H]+.
Embodiment 53
(2- ((2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- (trifluoromethyl)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 622[M+H]+.
Embodiment 54
(2- ((the bromo- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 632[M+H]+.
Embodiment 55
2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -4- ((2- (solutions of dimethyl phosphoryl
Base) phenyl) amino) pyrimidine -5- formonitrile HCN
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 579[M+H]+.
Embodiment 56
(((the chloro- 2- of 5- ((3- cyclopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 594[M+H]+.
Embodiment 57
(2- ((the chloro- 2- of 5- ((3- (difluoromethyl) -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 604[M+H]+.
Embodiment 58
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- (trifluoromethoxy) phenyl) ammonia
Base) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 638[M+H]+.
Embodiment 59
(2- ((the chloro- 2- of 5- ((3- ethyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 582[M+H]+.
Embodiment 60
(((the chloro- 2- of 5- ((3- isopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 596[M+H]+.
Embodiment 61
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- propyl phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 596[M+H]+.
Embodiment 62
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridin-3-yl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 589[M+H]+.
Embodiment 63
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridin-4-yl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 589[M+H]+.
Embodiment 64
(4- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -3-
Base) amino) pyridin-4-yl) dimethyl phosphorus
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 589[M+H]+.
Embodiment 65
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) pyridine -2- base) dimethyl phosphorus.
Synthetic method is referring to embodiment 1.
MS(ESI):m/z 589[M+H]+.
Embodiment 66
2- amino-metadiazine compound tests the activity suppression of Wild type EGFR and mutability EGFR kinases:
EGFR (WT) is wild-type egf receptor, and EGFR (T790M) is with the 790th amino acids by Soviet Union's ammonia
For acid mutation at the EGF-R ELISA of methionine, EGFR (L858R) is to be mutated with the 858th amino acids by leucine
At arginic EGF-R ELISA, EGFR (L861Q) is to be mutated into glutamy by leucine with the 861st amino acids
The EGF-R ELISA of amine, EGFR (L858R/T790M) are to be mutated into glutamy by leucine with the 858th amino acids
Amine, the 790th amino acids are mutated into the EGF-R ELISA of the double mutation of methionine by threonine.EGFR (L858R/
T790M/C797S) to be mutated into glutamine by leucine with the 858th amino acids, the 790th amino acids are dashed forward by threonine
Become methionine, the 797th EGF-R ELISA by three mutation that cysteine mutation is serine.
With enzyme linked immunosorbent assay (Enzyme-Linked Immunosorbent Assay, ELISA) detection compound pair
The inhibiting effect of kinase activity.EGFRWTAnd EGFRT790M/L858RKinases is purchased from Eurofins company, EGFRT790M/L858R/C797SRSwash
Enzyme is purchased from BPS Bioscience company.Steps are as follows for major experimental: enzyme reaction substrate Poly (Glu, Tyr)4:1With no potassium ion
PBS (10mM sodium phosphate buffer, 150mM NaCl, pH 7.2-7.4) be diluted to 20 μ g/mL, 37 DEG C of reaction 12-16h packets
By ELISA Plate.Every hole, which is added, uses reaction buffer (50mM HEPES pH 7.4,50mM MgCl2,0.5mM MnCl2,0.2 mM
Na3VO4, 1mM DTT) and diluted ATP (5 μM of final concentration) solution, untested compound or solvent control is added, then kinase promoter
Reaction, 37 DEG C of shaking tables react 1h.T-PBS board-washing three times, is added antibody PY99 in 37 DEG C of shaking tables and reacts 0.5h.T-PBS board-washing
Afterwards, the IgG of the sheep anti mouse of horseradish peroxidase-labeled is added, 37 DEG C of shaking tables react 0.5h.Again after board-washing, 2mg/mL is added
OPD developing solution, 25 DEG C are protected from light 1-10min.2M H is added2SO4Reaction is terminated, is declined orifice plate microplate reader with wavelengthtunable
SPECTRA MAX 190 is detected, and uses wavelength for 492nm.IC50Value is analyzed to obtain by suppression curve.
Be classified as compound number (corresponding with the compound number in above-described embodiment 1- embodiment 65) and change in table 1
Object is closed to the testing result of each kinase inhibiting activity.
Inhibitory activity result of 1 compound of table to kinases
Embodiment 67
Compound expresses EGFR to heightL858R/T790M/C797SBaF3 vehicles cells strain point of impact on target inhibiting effect experiment:
Using Western Blot method detection compound to EGFR in vehicles cellsL858R/T790M/C797SInhibitory activity.
By exogenous high expression EGFRL858R/T790M/C797SBaF3 vehicles cells be inoculated in 6 orifice plates, adhere-wall culture is overnight, uses no blood instead
Clear culture solution continues culture for 24 hours.Then, the compound effects 2h of various concentration is added, EGFR growth factor (50 is then added
Ng/mL it) acts on 10 minutes.Cell is cleaned with the PBS of pre-cooling, and in triplicate, remove remnants PBS, cracked with SDS lysate thin
Born of the same parents collect lysate using Western Blot method detection compound to EGFR in cellL858R/T790M/C797SInhibitory activity.
P-EGFR (Tyr1068) antibody, EGFR antibody used etc. are tested, it is public purchased from Cell Signaling Technologies
Department.
Be classified as compound number (corresponding with the compound number in above-described embodiment 1- embodiment 65) and change in table 2
Object is closed to the testing result of each vehicles cells strain proliferation inhibition activity.
The inhibitory activity result of 2 compound on intracellular of table proliferation
Each technical characteristic of embodiment described above can be combined arbitrarily, for simplicity of description, not to above-mentioned reality
It applies all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, all should be considered as described in this specification.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
It cannot therefore be construed as limiting the scope of the patent.It should be pointed out that coming for those of ordinary skill in the art
It says, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to protection of the invention
Range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (19)
1. 2- amino-metadiazine compound or its pharmaceutically acceptable salt or its alloisomerism with structure shown in Formulas I
Body or its prodrugs:
In formula:
D, E, F, W, X, Y, Z are separately selected from: CH or N;
R1And R2It is separately selected from: H, halogen, cyano, trifluoromethyl, nitro, substituted or unsubstituted C1-C6Alkyl, substitution
Or unsubstituted C3-C6Naphthenic base, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C3-C6Cycloalkyloxy;
R3It is selected from: hydrogen, halogen, cyano, trifluoromethyl, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C6Ring
Alkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C3-C6Cycloalkyloxy;
R4It is selected from: substituted or unsubstituted pyrazolyl ,-(CH2)mNR6R7、-(CH2)mOCR5R6R7、-(CH2)mCR5R6R7;
Wherein, m is selected from: 0,1,2,3 or 4;
R5It is selected from: hydrogen or C1-C3Alkyl;
R6And R7It is separately selected from: hydrogen, substituted or unsubstituted C1-C6Alkyl or R6、R7With mono- similar shape of N or C being connected
Contain heteroatomic monocycle or condensed ring at substituted or unsubstituted.
2. 2- amino-metadiazine compound according to claim 1 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that
R4It is selected from: R8Substituted pyrazolyl ,-(CH2)mNR6R7、-(CH2)mOCR5R6R7、-(CH2)mCR5R6R7;Wherein,
M is selected from: 0,1,2,3 or 4;
R5It is selected from: hydrogen or C1-C3Alkyl;
R6And R7It is separately selected from: hydrogen, R8Substituted C1-C6Alkyl or R6、R7R is formed together with the N or C being connected8It takes
In generation, contains n heteroatomic 3-8 unit monocycles or R6、R7R is formed together with the N or C being connected8What is replaced is heteroatomic containing n
8-12 member condensed ring, loop coil or bridged ring, n are selected from: 1,2 or 3, hetero atom is selected from: O, N, S;
R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, halogen, hydroxyl, amino, C1-C3Alkyl ,-C (=O) NHR9Substituted C1-C3
The C that alkyl, hydroxyl replace1-C3Alkyl, C3-C6The C that naphthenic base replaces1-C3Alkyl, C3-C8The C that heterocycle replaces1-C3Alkyl,
C1-C3Alkoxy ,-NHR9、-N(R9)2,-C (=O) R9;R9For C1-C3Alkyl.
3. 2- amino-metadiazine compound according to claim 2 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that R4It is selected from :-(CH2)mNR6R7;M is selected from: 0 or 1;
R6And R7It is separately selected from: hydrogen, R8Substituted C1-C6Alkyl or R6、R7R is formed together with the N being connected8Replace
Containing n heteroatomic 3-8 unit monocycles or R6、R7R is formed together with the N being connected8What is replaced is thick containing n heteroatomic 8-12 members
Ring, loop coil or bridged ring, wherein n is selected from: 1,2 or 3, hetero atom is selected from: O, N, S;
R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, halogen, hydroxyl, amino, C1-C3Alkyl, C1-C3Alkoxy ,-NHR9、-N
(R9)2,-C (=O) R9;R9For C1-C3Alkyl.
4. 2- amino-metadiazine compound according to claim 3 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that R8It is selected from: H, R9Substituted 4-8 circle heterocyclic ring base, C1-C3Alkyl ,-NHR9、-N
(R9)2;R9For C1-C3Alkyl.
5. 2- amino-metadiazine compound according to claim 2 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that R4It is selected from:
6. 2- amino-metadiazine compound according to claim 1-5 or its pharmaceutically acceptable salt or
Its stereoisomer or its prodrugs, which is characterized in that F is selected from: CH or N;D, E, W, X, Y, Z are CH.
7. 2- amino-metadiazine compound according to claim 1-5 or its pharmaceutically acceptable salt or
Its stereoisomer or its prodrugs, which is characterized in that R1And R2It is separately selected from: H, halogen, cyano, fluoroform
Base, nitro, C1-C6Alkyl, C3-C6Naphthenic base, C1-C6Alkoxy, C3-C6The C that cycloalkyloxy, halogen replace1-C6Alkyl, halogen
Substituted C1-C6Alkoxy.
8. 2- amino-metadiazine compound according to claim 7 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that R1Be selected from: halogen, methyl, cyano, trifluoromethyl, difluoromethyl, methoxyl group,
Cyclopropyl, trifluoromethoxy.
9. 2- amino-metadiazine compound according to claim 7 or its pharmaceutically acceptable salt or its solid are different
Structure body or its prodrugs, which is characterized in that R2It is selected from: halogen, C1-C6Alkyl, fluorine-substituted C1-C6Alkyl, C3-C6Cycloalkanes
Base, fluorine-substituted C3-C6Naphthenic base, C1-C6Alkoxy, fluorine-substituted C1-C6Alkoxy.
10. 2- amino-metadiazine compound according to claim 7 or its pharmaceutically acceptable salt or its solid
Isomers or its prodrugs, which is characterized in that R2It is selected from: fluorine, chlorine, bromine, methyl, ethyl, methoxyl group, trifluoromethyl, two
Methyl fluoride, trifluoromethoxy, cyclopropyl, isopropyl, n-propyl.
11. 2- amino-metadiazine compound according to claim 1-5 or its pharmaceutically acceptable salt or
Its stereoisomer of person or its prodrugs, which is characterized in that R3It is selected from: hydrogen, halogen, cyano, trifluoromethyl, nitro, C1-
C6Alkyl, C3-C6Naphthenic base, C1-C6Alkoxy, C3-C6The C that cycloalkyloxy, halogen replace1-C6The C that alkyl, halogen replace1-C6
Alkoxy.
12. 2- amino-metadiazine compound according to claim 11 or its pharmaceutically acceptable salt or its solid
Isomers or its prodrugs, which is characterized in that R3It is selected from: hydrogen, fluorine, chlorine, methyl, ethyl, cyano, trifluoromethyl, difluoro
Methyl, methoxyl group, cyclopropyl, trifluoromethoxy.
13. 2- amino-metadiazine compound according to claim 1 or its pharmaceutically acceptable salt or its solid
Isomers or its prodrugs, which is characterized in that the 2- amino-metadiazine compound is selected from:
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- trifluoromethyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) two
Methyl oxidation phosphorus;
(2- ((the chloro- 2- of 5- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -3- aminomethyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3aR, 6aS) -5- methyl hexahydropyrrolo [3,4-c] pyrroles -2 (1H)-yl) benzene
Base) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- methyl-1,4- phenodiazine heptane -1- base) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methoxyl group -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- methyl -6- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) pyridin-3-yl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (9- methyl -3,9- phenodiazine spiral shell [5.5] hendecane -3- base) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (7- methyl -2,7- phenodiazine spiral shell [3.5] nonane -2- base) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(S)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(R)-(2- ((the chloro- 2- of 5- ((4- (3,4- lupetazin -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- ((2- (dimethylamino) ethyl) (methyl) amino) -6- picoline -2- base) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- ((3R, 5S) -3,4,5- tri methyl piperazine -1- base) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((1- (2- (diethylamino) ethyl) -1H- pyrazoles -4- base) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- methyl -4- (4- (oxetanes -3- base) piperazine -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((5- (piperazine -1- ylmethyl) pyridine -2- base) amino) pyrimidine-4-yl) amino) phenyl) dimethyl
Phosphorous oxide;
(2- ((the chloro- 2- of 5- ((3- methoxyl group -4- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- ethyl piperazidine -1- base) -3- aminomethyl phenyl) amino) pyrimidine-4-yl) amino) phenyl) two
Methyl oxidation phosphorus;
(2- ((2- ((the bromo- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) -5- chlorine pyrimidine-4-yl) amino) phenyl) diformazan
Base phosphorous oxide;
(2- ((2- ((the bromo- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- chlorine pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((6- methyl -5- (4- methylpiperazine-1-yl) pyridine 2- yl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((5- chlorine 2- ((3- methyl -4- (piperidin-4-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl
Phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- (dimethylamino) piperidin-1-yl) -3- aminomethyl phenyl) amino) pyrimidine 4- yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) diformazan
Base phosphorous oxide;
(2- ((the chloro- 2- of 5- ((4- (4- methylpiperazine-1-yl) -3- trifluoromethyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the fluoro- 4- of 3- (4- methylpiperazine-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) diformazan
Base phosphorous oxide;
(2- ((the chloro- 2- of 5- ((the chloro- 4- morpholino phenyl of 3-) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2- base) phenyl)
Amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
1- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) phenyl) piperazine
Piperazine -1- base) ethyl -1- ketone;
2- (4- (the chloro- 4- of 2- ((the chloro- 4- of 5- ((2- (solutions of dimethyl phosphoryl base) phenyl) amino) pyrimidine -2-base) amino) phenyl) piperazine
Piperazine -1- base)-N- methylacetamide;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (2- ethoxy) piperazine -1- base) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- hydroxy piperidine -1- base) phenyl) amino) pyrimidine-4-yl) amino) phenyl) diformazan
Base phosphorous oxide;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (dimethylamino) heterocyclic butane -1- base) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (methyl (2- (methylamino) ethyl) amino) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (cyclopropyl alkyl methyl) piperazine -1- base) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- ((1S, 4S) -5- methyl -2,5- diazabicylo [2.2.1] heptane -2- base) piperazine
Pyridine -1- base) phenyl) amino) pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- morpholinyl piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino) phenyl) two
Methyl oxidation phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methyl-1,4- diaza heptane -1- base) piperidin-1-yl) phenyl) amino)
Pyrimidine-4-yl) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (3- (piperidin-1-yl) pyrrolidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (pyrrolidin-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) amino)
Phenyl) dimethyl phosphorus;
(2- ((2- ((4- (4- (azetidine -1- ylmethyl) piperidin-1-yl) -3- chlorphenyl) amino) -5- chlorine pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((2- ((4- ([bis- piperidines of 1,4'-] -1'- base) -3- chlorphenyl) amino) -5- chlorine pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- chlorine 4- (3- (pyrrolidin-1-yl) propoxyl group) phenyl) amino) pyrimidine-4-yl) amino) phenyl)
Dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methylpyrrolidin- 3- yl) oxygroup) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- ((1- methyl piperidine -4- base) oxygroup) phenyl) amino) pyrimidine-4-yl) amino) benzene
Base) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (1- (piperidin-4-yl) -1H- pyrazoles -4- base) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
(((2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -5- (trifluoromethyl) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the bromo- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) phenyl) dimethyl phosphorus;
2- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) -4- ((2- (solutions of dimethyl phosphoryl base)
Phenyl) amino) pyrimidine -5- formonitrile HCN;
(2- ((the chloro- 2- of 5- ((3- cyclopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- difluoromethyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -
4- yl) amino) phenyl) dimethyl phosphorus;
(((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- (trifluoromethoxy) phenyl) amino) is phonetic by 2-
Pyridine -4- base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- ethyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((3- isopropyl -4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine -4-
Base) amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((4- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) -3- propyl phenyl) amino) pyrimidine-4-yl)
Amino) phenyl) dimethyl phosphorus;
(2- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) pyridin-3-yl) dimethyl phosphorus;
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) pyridin-4-yl) dimethyl phosphorus;
(4- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidin-3-yl) ammonia
Base) pyridin-4-yl) dimethyl phosphorus;
(3- ((the chloro- 2- of 5- ((the chloro- 4- of 3- (4- (4- methylpiperazine-1-yl) piperidin-1-yl) phenyl) amino) pyrimidine-4-yl) ammonia
Base) pyridine -2- base) dimethyl phosphorus.
14. the described in any item 2- amino-metadiazine compounds of claim 1-13 or its pharmaceutically acceptable salt or its
Stereoisomer or its prodrugs are preparing the application in mutant egf R inhibitor.
15. the described in any item 2- amino-metadiazine compounds of claim 1-13 or its pharmaceutically acceptable salt or its
The application of stereoisomer or its prodrugs in the drug for preparing anti-curing oncoma.
16. application according to claim 15, which is characterized in that the tumour is the malignant tumour of EGFR genetic mutation.
17. application according to claim 16, which is characterized in that the tumour is EGFRL858R/T790M/C797SThe evil of mutation
Property tumour.
18. application according to claim 16, which is characterized in that the tumour are as follows: non-small cell lung cancer, cellule lung
It is cancer, adenocarcinoma of lung, lung squamous cancer, cancer of pancreas, breast cancer, prostate cancer, liver cancer, cutaneum carcinoma, cell carcinoma, gastrointestinal stromal tumor, white
Blood disease, histiocytic lymph cancer, nasopharyngeal carcinoma, head and neck neoplasm, colon and rectum carcinoma or glioma.
19. a kind of pharmaceutical composition of anti-curing oncoma, which is characterized in that including active constituent and pharmaceutically acceptable load
Body, the active constituent includes the described in any item 2- amino-metadiazine compounds of claim 1-13 or it pharmaceutically may be used
The salt of receiving or its stereoisomer or its prodrugs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810230760X | 2018-03-20 | ||
CN201810230760 | 2018-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110305161A true CN110305161A (en) | 2019-10-08 |
Family
ID=68074349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910208004.1A Pending CN110305161A (en) | 2018-03-20 | 2019-03-19 | 2- amino-metadiazine compound and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110305161A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110467637A (en) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | A kind of double amino Chloropyrimide class compounds containing phosphinoxides substituted aniline, preparation method and applications |
CN110467638A (en) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | A kind of double amino Chloropyrimide class compounds containing m-chloroaniline class substituent group, preparation method and applications |
WO2020088390A1 (en) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | Pyrimidopyrazole compounds as fourth generation egfr inhibitors |
CN112824420A (en) * | 2019-11-21 | 2021-05-21 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
CN114507143A (en) * | 2022-02-26 | 2022-05-17 | 江苏壹药新材料有限公司 | Synthesis method of 2-ethyl-1-fluoro-4-nitrobenzene |
WO2022211573A1 (en) * | 2021-04-01 | 2022-10-06 | 주식회사 테라펙스 | Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same |
WO2023006088A1 (en) * | 2021-07-30 | 2023-02-02 | 浙江大学智能创新药物研究院 | Compound for egfr kinase inhibitor, composition and use thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102105150A (en) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | Phosphorous derivatives as kinase inhibitors |
CN104814970A (en) * | 2010-10-14 | 2015-08-05 | 阿里亚德医药股份有限公司 | Methods for inhibiting cell proliferation in egfr-driven cancers |
CN105330698A (en) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | Spiro aryl phosphorus oxide or sulfide |
CN105601573A (en) * | 2014-11-24 | 2016-05-25 | 中国科学院上海药物研究所 | 2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof |
CN106220608A (en) * | 2016-07-25 | 2016-12-14 | 张柏 | Diphenylamino pyrimidine and triaizine compounds, its Pharmaceutical composition and purposes |
WO2017086829A1 (en) * | 2015-11-19 | 2017-05-26 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Dichloroacetates of substituted n4-[2-(dimethylphosphinoyl)phenyl]-n2-(2-methoxy-4-piperidin-1-ylphenyl)-5-chloropyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer |
WO2017086832A1 (en) * | 2015-11-19 | 2017-05-26 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | Substituted n2-(4-amino-2-methoxyphenyl)-n4-[2-(dimethylphosphinoyl)-phenyl]-5-chloro-pyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer |
CN106928275A (en) * | 2015-12-29 | 2017-07-07 | 齐鲁制药有限公司 | The Preparation Method And Their Intermediate and crystal formation of volution amine aryl phosphoric-oxygenic compound |
CN107216319A (en) * | 2016-03-21 | 2017-09-29 | 中国科学院上海药物研究所 | A kind of 2,4- di-amino-pyrimidines analog derivative, preparation method and the usage |
CN107417626A (en) * | 2016-05-23 | 2017-12-01 | 江苏奥赛康药业股份有限公司 | A kind of polymorphic forms of 2 amino-metadiazine compound |
WO2018108064A1 (en) * | 2016-12-13 | 2018-06-21 | 南京明德新药研发股份有限公司 | Spiro-aryl-phosphorus-oxygen compound as fourth generation of egfr kinase inhibitor |
-
2019
- 2019-03-19 CN CN201910208004.1A patent/CN110305161A/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102105150A (en) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | Phosphorous derivatives as kinase inhibitors |
CN104814970A (en) * | 2010-10-14 | 2015-08-05 | 阿里亚德医药股份有限公司 | Methods for inhibiting cell proliferation in egfr-driven cancers |
CN105330698A (en) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | Spiro aryl phosphorus oxide or sulfide |
CN105601573A (en) * | 2014-11-24 | 2016-05-25 | 中国科学院上海药物研究所 | 2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof |
WO2017086829A1 (en) * | 2015-11-19 | 2017-05-26 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Dichloroacetates of substituted n4-[2-(dimethylphosphinoyl)phenyl]-n2-(2-methoxy-4-piperidin-1-ylphenyl)-5-chloropyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer |
WO2017086832A1 (en) * | 2015-11-19 | 2017-05-26 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | Substituted n2-(4-amino-2-methoxyphenyl)-n4-[2-(dimethylphosphinoyl)-phenyl]-5-chloro-pyrimidine-2,4-diamines as alk and egfr modulators intended for treating cancer |
CN106928275A (en) * | 2015-12-29 | 2017-07-07 | 齐鲁制药有限公司 | The Preparation Method And Their Intermediate and crystal formation of volution amine aryl phosphoric-oxygenic compound |
CN107216319A (en) * | 2016-03-21 | 2017-09-29 | 中国科学院上海药物研究所 | A kind of 2,4- di-amino-pyrimidines analog derivative, preparation method and the usage |
CN107417626A (en) * | 2016-05-23 | 2017-12-01 | 江苏奥赛康药业股份有限公司 | A kind of polymorphic forms of 2 amino-metadiazine compound |
CN106220608A (en) * | 2016-07-25 | 2016-12-14 | 张柏 | Diphenylamino pyrimidine and triaizine compounds, its Pharmaceutical composition and purposes |
WO2018108064A1 (en) * | 2016-12-13 | 2018-06-21 | 南京明德新药研发股份有限公司 | Spiro-aryl-phosphorus-oxygen compound as fourth generation of egfr kinase inhibitor |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110467637A (en) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | A kind of double amino Chloropyrimide class compounds containing phosphinoxides substituted aniline, preparation method and applications |
CN110467638A (en) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | A kind of double amino Chloropyrimide class compounds containing m-chloroaniline class substituent group, preparation method and applications |
CN110467637B (en) * | 2018-05-09 | 2022-02-18 | 北京赛特明强医药科技有限公司 | Bisaminyl chloropyrimidine compound containing phosphine oxide substituted aniline, preparation method and application thereof |
CN112771032A (en) * | 2018-10-29 | 2021-05-07 | 江苏先声药业有限公司 | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors |
WO2020088390A1 (en) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | Pyrimidopyrazole compounds as fourth generation egfr inhibitors |
CN112771032B (en) * | 2018-10-29 | 2023-01-03 | 江苏先声药业有限公司 | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors |
CN112824420A (en) * | 2019-11-21 | 2021-05-21 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
WO2021098883A1 (en) * | 2019-11-21 | 2021-05-27 | 浙江同源康医药股份有限公司 | Compound used as egfr kinase inhibitor and use thereof |
CN112824420B (en) * | 2019-11-21 | 2022-04-26 | 浙江同源康医药股份有限公司 | Compounds useful as EGFR kinase inhibitors and uses thereof |
AU2020385527B2 (en) * | 2019-11-21 | 2023-04-13 | Tyk Medicines, Inc. | Compound used as EGFR kinase inhibitor and use thereof |
WO2022211573A1 (en) * | 2021-04-01 | 2022-10-06 | 주식회사 테라펙스 | Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same |
WO2023006088A1 (en) * | 2021-07-30 | 2023-02-02 | 浙江大学智能创新药物研究院 | Compound for egfr kinase inhibitor, composition and use thereof |
CN114507143A (en) * | 2022-02-26 | 2022-05-17 | 江苏壹药新材料有限公司 | Synthesis method of 2-ethyl-1-fluoro-4-nitrobenzene |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110305161A (en) | 2- amino-metadiazine compound and its application | |
CN106458930B (en) | 2- amino-metadiazine compound and its pharmaceutical composition and application | |
TWI549954B (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
CN102762557B (en) | Triazolopyridine | |
KR102019643B1 (en) | 8-carbamoyl-2-(2,3-disubstituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
CN103012399B (en) | 7-oxopyridinopyrimidine compound as well as medicinal composition and application thereof | |
US20160193206A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
TW200924776A (en) | Heteroaryl compounds and uses thereof | |
CN113166110B (en) | 2-aminopyrimidine compound and application thereof | |
TW200808776A (en) | Kinase inhibitors | |
AU2009286982C1 (en) | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275)polymorph B | |
TW201245194A (en) | Triazolopyridines | |
CN105518001A (en) | Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones | |
CN106573931A (en) | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups | |
AU2017326029B2 (en) | Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof | |
AU2019241374A1 (en) | Quinoline or quinazoline compound and application thereof | |
WO2015193228A1 (en) | Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino- or ether groups | |
US20190169199A1 (en) | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors | |
CN103570731B (en) | Pyrimido three encircles or pyrimido Fourth Ring compounds and Pharmaceutical composition and application | |
WO2020192302A1 (en) | Pyrimidine-containing tri-substituted imidazole compound and application thereof | |
CN103649087A (en) | Substituted imidazopyridines and intermediates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |